Do you have $10,000 to invest into ASX 200 shares in January? If you do, then it could be worth considering the two shares in this article.
Let's see why they could be great options for investors this month:
Neuren Pharmaceuticals Ltd (ASX: NEU)
The first ASX 200 share to consider for a $10,000 investment in January is Neuren Pharmaceuticals.
It is a pharmaceuticals company that is focused on developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.
Bell Potter is very bullish on the company. This is partly due to the potential of its NNZ-2591 therapy, which is under development at present. Its analysts said:
Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.
The broker currently has a buy rating and $25.00 price target on its shares. Based on its current share price of $12.20, this implies potential upside of just over 100% for investors between now and this time next year.
Xero Ltd (ASX: XRO)
Another ASX 200 share that could be a good option for a $10,000 investment in January is Xero.
It is a leader in cloud accounting across New Zealand, Australia, and the United Kingdom. Its online accounting software connects small business owners with their numbers, their bank, and advisors at anytime.
Goldman Sachs is a big fan of Xero. This is due to its huge total addressable market (TAM), which gives it a huge growth runway over the coming decades. Goldman highlights that Xero's TAM is over 100 million small to medium sized businesses (SMBs), which compares to its current subscriber base of 4.2 million. The broker said:
Xero is a Global Cloud Accounting SaaS player, with existing focuses in ANZ, UK, North American and SE Asian markets. We see Xero as very well-placed to take advantage of the digitisation of SMBs globally, driven by compelling efficiency benefits and regulatory tailwinds, with >100mn SMBs worldwide representing a >NZ$100bn TAM.
Given the company's pivot to profitable growth and corresponding faster earnings ramp, we see an attractive entry point into a global growth story with Xero our preferred large-cap technology name in ANZ – the stock is Buy rated.
Goldman has a buy rating and $201.00 price target on the company's shares. Based on its current share price of $168.17, this implies potential upside of approximately 20% for investors over the next 12 months.
